RxDoctor Payments DataLook up a doctor →

Michelle Sitzman, PA

Medical · Lincoln, NENPI 1568469419

Payments from drug & device makers

$206,268in general payments, 2019–2025

Across 907 payments — averaging $227.42 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Arcutis Biotherapeutics, Inc.$53K
  • Incyte Corporation$38K
  • Regeneron Healthcare Solutions, Inc.$36K
  • AbbVie$29K
  • Galderma Laboratories, L.p.$25K
  • Sanofi$11K
  • plus $14K from 18 others

What the payments were for

  • Consulting fees$35,41317%
  • Speaking & faculty fees$120,78159%
  • Travel & lodging$34,66617%
  • Food & beverage$14,6067%
  • Education$8020%

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$206,268 in reported general payments places this provider in the 95th percentile of 216 medical providers in Nebraska.

See all medical providers in Nebraska

Medicare billing

Part B allowed, 2024
$224,713
Medicare patients
1,122
Services billed
6,719

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OtezlaApremilast16$114,492
Dupixent PenDupilumab29$109,490
Taltz AutoinjectorIxekizumab12$81,119
Dupixent SyringeDupilumab16$70,621
Doxycycline Ir-DrDoxycycline Monohydrate11$4,069
Metronidazole32$2,119
Clobetasol Propionate51$1,973
Imiquimod66$1,903
Ketoconazole109$1,570
ValacyclovirValacyclovir Hcl29$1,120
Betamethasone Dipropionate28$1,027
Minocycline Hcl25$887
Triamcinolone Acetonide93$859
Tretinoin11$494
Mometasone Furoate18$388

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AmgenOtezla$57$114,49216 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 216 medical providers in Nebraska.

Other medical in Lincoln

See the full list for Nebraska

Where these figures come from

Is this you, or does something look wrong? →